ClinicalTrials.gg
RecruitingNCT05709249Updated Dec 30, 2024

Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer

A Phase 3 interventional study of XLJDOD compound granule and placebo (XLJDOD mimetic agent) in Colon Cancer, sponsored by Jiangsu Famous Medical Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-30.

Sponsored by Jiangsu Famous Medical Technology Co., Ltd. · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
730
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 211 studies in Colonic Neoplasms with a site in China — 101 open to participants now, 117 under way, 22 of them phase 3. Colonic Neoplasms · China.

Planned enrollment
24th of 163
730 · median 110
Started
2022
with 23 others
Phase 3
28 of 211
15 open now
Primary completion
2027-04
later than 67 of 116 live
Registered
117th of 211
by date

Among the 211 studies in Colonic Neoplasms with a site in China, this one is the 24th largest by planned enrollment of the 163 interventional ones that give a count, is one of 24 that started in 2022, is one of 28 in phase 3, reaches primary completion later than 67 of the 116 other live ones, and was the 117th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

101 of the 211 studies in Colonic Neoplasms with a site in China are open now. Recruiting first, the newest first:

96 more — sign in →

All 101 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 211 studies in Colonic Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is designed as a multi-center, randomized, double-blind, placebo-controlled trial. Subjects in the intervention group will be treated with XLJDOD compound granule. Subjects in the control group will be treated with placebo (XLJDOD mimetic agent).

Read the detailed description

Subjects in the intervention group will be treated with XLJDOD compound granule. Treatment will begin within 3 months after standard adjuvant chemotherapy and compliance will be continuously monitored. XLJDOD will be taken twice a day, infused with warm water, 1 hour after lunch and dinner. One course of treatment will take 28 days in 1 month, and 2- to 3-day rest. Treatment will continue for 6 courses. Subjects in the control group will be treated with placebo (XLJDOD mimetic agent). The course of placebo in control group will be in accordance with that of XLJDOD in intervention group.

03

Conditions studied

  • Colon Cancer

Browse trials for

Keywords

  • colon cancer
  • Traditional Chinese medicine
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Colon carcinoma confirmed by pathology.*

    *Preoperative endoscopy showed that the distal end of the tumor was ≥12cm from the anal margin. If the patient did not undergo endoscopic examination before surgery, the distance of the tumor from the anal margin was ≥12cm according to the results of intraoperative examination or preoperative imaging examination.

  2. Completion of surgical resection of tumors with negative margins (R0 resection) and at least 3 months of chemotherapy based on 5-fluorouracil (5-FU). *

    *4 cycles of CAPOX (capecitabine and oxaliplatin), 6 cycles of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or 4 cycles of single agent-5-FU, etc.

  3. Within 3 months after the completion of adjuvant chemotherapy.
  4. Patients with Stage IIIB or IIIC disease.*

    *IIIB: T3-T4aN1/N1cM0, T2-T3N2aM0 and T1-T2N2bM0, IIIC: T4aN2aM0, T3-T4aN2bM0 and T4bN1-N2M0, as defined by the American Joint Committee on Cancer (AJCC) 8th edition).

  5. Aged 20-80 years, men or women.
  6. (ECOG) performance status of 0-2.
  7. With no radiographic evidence of tumor recurrence.
  8. Sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Presence of other in the past 5 years except curatively treated basal cell carcinoma or cervical carcinoma in situ.
  2. Besides chemotherapy, other adjuvant therapy such as radiotherapy, targeted therapy and immunotherapy has been used to treat colon cancer.
  3. Antitumor Chinese patent medicine and decoction have been used for more than 3 months after surgery or within 1 month before enrollment.
  4. Patients with severe comorbidities such as cardiovascular, cerebrovascular, renal, hepatic, hematopoietic system and other severe primary diseases.
  5. Allergic to the ingredients of XLJDOD.
  6. Any condition that is unstable or can jeopardize the safety of the patients and their compliance to the study, including pregnancy, plan to be pregnant, lactation and psychiatric disorders (schizophrenia, depression, and obsessive-compulsive disorder, etc.).
  7. Suspected or confirmed history of alcohol and drug abuse.
  8. Patients with other conditions considered by the investigator should not participate in the study.
  9. Patients who have recently participated in or are currently participating in other clinical trials of drugs.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
730 participants (estimated)

Study arms

  • Active comparator
    intervention group

    Subjects in the intervention group will be treated with XLJDOD compound granule.

    Drug: XLJDOD compound granule

  • Placebo comparator
    control group

    Subjects in the control group will be treated with placebo (XLJDOD mimetic agent).

    Drug: placebo (XLJDOD mimetic agent)

Interventions

  • DrugXLJDOD compound granule

    Treatment will begin within 3 months after standard adjuvant chemotherapy and compliance will be continuously monitored. XLJDOD will be taken twice a day, infused with warm water, 1 hour after lunch and dinner. One course of treatment will take 28 days in 1 month, and 2- to 3-day rest. Treatment will continue for 6 courses.

  • Drugplacebo (XLJDOD mimetic agent)

    The course of placebo in control group will be in accordance with that of XLJDOD in intervention group.

06

What researchers measure

Primary outcomes

  1. Two-year disease-free survival (DFS)

    2-year DFS is defined as the percentage of patients alive without disease recurrence at 2 years measured from the randomization date.

    Time frame: Assess once 24 months after randomization

Secondary outcomes

  1. Three-year disease-free survival (DFS)

    3-year DFS is defined as the percentage of patients alive without disease recurrence at 3 years measured from the randomization date.

    Time frame: Assess once 36 months after randomization

  2. One, two, three-year relapse rate (RR)

    RR is defined as the fraction of followed patients who have disease recurrence. All disease recurrences and deaths from colon cancer are events. Second primary same cancers and other primary cancers will be ignored.

    Time frame: Assess at month 12, 24, 36 after randomization

  3. Three-year survival rate

    3-year survival rate is defined as the percentage of patients alive at 3 years measured from the randomization date.

    Time frame: Assess once 36 months after randomization

  4. Overall survival (OS)

    OS is measured from the date of enrollment to the date of death, irrespective of cause.

    Time frame: Observation to the end of the study,assessed up to 24 months

  5. Changes in total score on the EORTCQLQ-C30 Scale

    The changes of The European O-rganization for Reasearch and Treatment of Cancer score will be compared in the two groups prior to and following XLJDOD compound granule administration. It is a universal scale for all patients with malignant tumors with a total score of 126, ranging from 30 (least severe) to 126 (most severe).

    Time frame: Measurement will be performed at baseline and month 6, 12 ,18 ,24, 36.

  6. Changes in total score on the MD Anderson Symptom Inventory for Traditional Chinese Medicine (MDASI-TCM)

    The scale is divided into two parts. The first part mainly assesses the severity of 20 common clinical symptoms and TCM-related symptoms of patients with cancer in the past 24 hours. The second part is the evaluation scale of the interference of the above symptoms with daily functioning. It has a total of 26 items, each with a score of 0-10, leading to a total score of 0-260.

    Time frame: Compared with the baseline period, the changes in MDASI-TCM score at month 6, 12 ,18 ,24, 36 will be measured.

07

Study locations

1 of 1 sites recruiting
  • Jiangsu Province Hospital of Traditional Chinese Medicine
    Nanjing, China
    Recruiting
    • Yujia Wang · Contact18120192802
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Apr 2027, 52 months after the start.

Of 72 phase 3 interventional studies under Colonic Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 119. This study's planned 52 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2023
First posted
Feb 2, 2023
StartActual
Dec 1, 2022
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2028
Last update
Dec 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05709249
Lead sponsor
Jiangsu Famous Medical Technology Co., Ltd.
Collaborators
Jiangsu Province Hospital of Traditional Chinese Medicine, Ministry of Science and Technology of the People's Republic of China
Responsible party
Sponsor
First posted
Feb 2, 2023
Start date
Dec 1, 2022
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Dec 30, 2024

Study contacts

Yujia Wang
Contact
1217909635@qq.com
18120192802

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion